PCAR 119

Drug Profile

PCAR 119

Alternative Names: PCAR-119

Latest Information Update: 08 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PersonGen Biomedicine
  • Class Cell therapies
  • Mechanism of Action CD19 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia; Lymphoma

Most Recent Events

  • 01 Sep 2016 Phase-I/II clinical trials in Leukaemia (In children, In adolescents, In adults, In elderly) in China (Parenteral) (NCT02892695)
  • 01 Sep 2016 Phase-I/II clinical trials in Lymphoma (In children, In adolescents, In adults, In the elderly) in China (Parenteral) (NCT02892695)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top